The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome


Autoria(s): MACEDO, CAROLINA SALES VIEIRA; MARTINS, WELLINGTON P.; FERNANDES, JANAINA BOLDRINI FRANÇA; SOARES, GUSTAVO MAFALDO; REIS, ROSANA MARIA DOS; SÁ, MARCOS FELIPE SILVA DE; FERRIANI, RUI ALBERTO
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

21/08/2013

21/08/2013

01/09/2012

Resumo

Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder associated with metabolic dysfunction and changes in cardiovascular risk markers, and using oral contraceptives (OCs) may exert a further negative effect on these alterations in patients with PCOS. Thus, the primary objective of this study was to assess the effects on arterial function and structure of an OC containing chlormadinone acetate (2 mg) and ethinylestradiol (30 mcg), alone or combined with spironolactone (OC+SPL), in patients with PCOS. Study Design: This was a randomized, controlled clinical trial. Fifty women with PCOS between 18 and 35 years of age were randomized by a computer program to use OC or OC+SPL. Brachial artery flow-mediated vasodilation, carotid intima-media thickness and the carotid artery stiffness index were evaluated at baseline and after 6 and 12 months. Serum markers for cardiovascular disease were also analyzed. The intragroup data were analyzed using analysis of variance with Tukey's post hoc test. A multivariate linear regression model was used to analyze the intergroup data. Results: At 12 months, the increase in mean total cholesterol levels was greater in the OC+SPL group than in the OC group (27% vs. 13%, respectively; p=.02). The increase in mean sex hormone-binding globulin levels was greater in the OC group than in the OC+SPL group (424% vs. 364%, respectively; p=.01). No statistically significant differences between the groups were found for any of the other variables. Conclusion: The addition of spironolactone to an OC containing chlormadinone acetate and ethinylestradiol conferred no cardiovascular risk-marker advantages in young women with PCOS. (C) 2012 Elsevier Inc. All rights reserved.

Waldemar B. Pessoa Foundation

Waldemar B. Pessoa Foundation

National Institute of Hormones and Womens Health, National Council for Scientific and Technological Development (CNPq)

National Institute of Hormones and Women's Health, National Council for Scientific and Technological Development (CNPq)

Identificador

CONTRACEPTION, NEW YORK, v. 86, n. 3, pp. 268-275, SEP, 2012

0010-7824

http://www.producao.usp.br/handle/BDPI/32646

10.1016/j.contraception.2011.12.011

http://dx.doi.org/10.1016/j.contraception.2011.12.011

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

NEW YORK

Relação

Contraception

Direitos

closedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #CONTRACEPTIVES #ORAL #HORMONAL #CARDIOVASCULAR DISEASES #POLYCYSTIC OVARY SYNDROME #SPIRONOLACTONE #COMBINED ORAL-CONTRACEPTIVES #ENDOTHELIAL FUNCTION #ARTERIAL STIFFNESS #INSULIN-RESISTANCE #BRACHIAL-ARTERY #NONOBESE WOMEN #THERAPY #DISEASE #HYPERTENSION #ASSOCIATION #OBSTETRICS & GYNECOLOGY
Tipo

article

original article

publishedVersion